# The STEP UP trial evaluated semaglutide 7.2 mg, 2.4 mg, and placebo over 72 weeks.

*biotech · news · 2026-05-12 · Benzinga*

## Key points

- Participants taking 7.2 mg Wegovy lost an average of 21% of their body weight over 72 weeks.
- New STEP UP analysis shows 27% of 7.2 mg patients were early responders, losing ≥15% in 24 weeks.
- MRI sub-analysis found 84% of semaglutide-induced weight loss was from reduced fat mass.
- Muscle function was preserved as assessed by a sit-to-stand test despite muscle mass reduction.

**Companies:** Novo Nordisk

[Read the full story on Benzinga](https://www.benzinga.com/news/health-care/26/05/52498930/novo-nordisk-presents-new-wegovy-data-showing-strong-weight-loss-fat-reduction)

---

Canonical: https://newsio.io/n/cd62b8f2-373b-4e5b-86b2-479efa18e472/the-step-up-trial-evaluated-semaglutide-7-2-mg-2-4-mg-and-placebo-over-72-weeks
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works